State of the art treatment of lung cancer: non-small cell lung cancer--surgical treatment

Research output: Contribution to journalArticle

Abstract

Surgery is defined as purely a local treatment modality. In the treatment of non-small cell lung cancer, surgery remains the first-line treatment of choice for local diseases. Thus, stages I, II, and a part of IIIA disease are definite indications for surgical therapy. The standard operative mode in curative intent for such local diseases is the resection of the entire lobe or lung where the cancer is located. The prognostic significance of hilar/mediastinal lymph node dissection remains controversial, although it can provide the most accurate information regarding the metastatic status of hilum and mediastinum. For locally advanced diseases of stages IIIA and IIIB, the surgical approach still remains investigational in a combined modality setting. For N2 diseases (with mediastinal node metastasis), the prognostic benefit of both preoperative and postoperative chemo (-radio) therapy has not been definitively demonstrated yet, although several reports suggested their potential benefits. They await further evaluation by clinical trials in a phase III setting. Although aggressive surgical approaches for tumors invading surrounding vital structures (IIIB disease) have been reported, it is also still uncertain whether their results can really exceed those obtained by chemoradiotherapy.

Original languageEnglish
Pages (from-to)366-372
Number of pages7
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume24 Suppl 3
Publication statusPublished - 1997 Oct
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Mediastinal Diseases
Therapeutics
Mediastinum
Chemoradiotherapy
Lymph Node Excision
Radio
Clinical Trials
Neoplasm Metastasis
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

State of the art treatment of lung cancer : non-small cell lung cancer--surgical treatment. / Asamura, Hisao.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 24 Suppl 3, 10.1997, p. 366-372.

Research output: Contribution to journalArticle

@article{3ec23f78ef734fb58fead337690ed806,
title = "State of the art treatment of lung cancer: non-small cell lung cancer--surgical treatment",
abstract = "Surgery is defined as purely a local treatment modality. In the treatment of non-small cell lung cancer, surgery remains the first-line treatment of choice for local diseases. Thus, stages I, II, and a part of IIIA disease are definite indications for surgical therapy. The standard operative mode in curative intent for such local diseases is the resection of the entire lobe or lung where the cancer is located. The prognostic significance of hilar/mediastinal lymph node dissection remains controversial, although it can provide the most accurate information regarding the metastatic status of hilum and mediastinum. For locally advanced diseases of stages IIIA and IIIB, the surgical approach still remains investigational in a combined modality setting. For N2 diseases (with mediastinal node metastasis), the prognostic benefit of both preoperative and postoperative chemo (-radio) therapy has not been definitively demonstrated yet, although several reports suggested their potential benefits. They await further evaluation by clinical trials in a phase III setting. Although aggressive surgical approaches for tumors invading surrounding vital structures (IIIB disease) have been reported, it is also still uncertain whether their results can really exceed those obtained by chemoradiotherapy.",
author = "Hisao Asamura",
year = "1997",
month = "10",
language = "English",
volume = "24 Suppl 3",
pages = "366--372",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

}

TY - JOUR

T1 - State of the art treatment of lung cancer

T2 - non-small cell lung cancer--surgical treatment

AU - Asamura, Hisao

PY - 1997/10

Y1 - 1997/10

N2 - Surgery is defined as purely a local treatment modality. In the treatment of non-small cell lung cancer, surgery remains the first-line treatment of choice for local diseases. Thus, stages I, II, and a part of IIIA disease are definite indications for surgical therapy. The standard operative mode in curative intent for such local diseases is the resection of the entire lobe or lung where the cancer is located. The prognostic significance of hilar/mediastinal lymph node dissection remains controversial, although it can provide the most accurate information regarding the metastatic status of hilum and mediastinum. For locally advanced diseases of stages IIIA and IIIB, the surgical approach still remains investigational in a combined modality setting. For N2 diseases (with mediastinal node metastasis), the prognostic benefit of both preoperative and postoperative chemo (-radio) therapy has not been definitively demonstrated yet, although several reports suggested their potential benefits. They await further evaluation by clinical trials in a phase III setting. Although aggressive surgical approaches for tumors invading surrounding vital structures (IIIB disease) have been reported, it is also still uncertain whether their results can really exceed those obtained by chemoradiotherapy.

AB - Surgery is defined as purely a local treatment modality. In the treatment of non-small cell lung cancer, surgery remains the first-line treatment of choice for local diseases. Thus, stages I, II, and a part of IIIA disease are definite indications for surgical therapy. The standard operative mode in curative intent for such local diseases is the resection of the entire lobe or lung where the cancer is located. The prognostic significance of hilar/mediastinal lymph node dissection remains controversial, although it can provide the most accurate information regarding the metastatic status of hilum and mediastinum. For locally advanced diseases of stages IIIA and IIIB, the surgical approach still remains investigational in a combined modality setting. For N2 diseases (with mediastinal node metastasis), the prognostic benefit of both preoperative and postoperative chemo (-radio) therapy has not been definitively demonstrated yet, although several reports suggested their potential benefits. They await further evaluation by clinical trials in a phase III setting. Although aggressive surgical approaches for tumors invading surrounding vital structures (IIIB disease) have been reported, it is also still uncertain whether their results can really exceed those obtained by chemoradiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0031255941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031255941&partnerID=8YFLogxK

M3 - Article

C2 - 9369909

AN - SCOPUS:0031255941

VL - 24 Suppl 3

SP - 366

EP - 372

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

ER -